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The effect of an antenatal lifestyle
intervention in overweight and obese
women on circulating cardiometabolic and
inflammatory biomarkers: secondary
analyses from the LIMIT randomised trial
Lisa J. Moran1,2, Louise M. Fraser1, Tulika Sundernathan1, Andrea R. Deussen1, Jennie Louise1,3, Lisa N. Yelland1,3,4,
Rosalie M. Grivell1,5, Anne Macpherson1, Matthew W. Gillman6,7, Jeffrey S. Robinson1, Julie A. Owens1
and Jodie M. Dodd1,8*
Abstract
Background: Maternal overweight and obesity during pregnancy is associated with insulin resistance,
hyperglycaemia, hyperlipidaemia and a low-grade state of chronic inflammation. The aim of this pre-specified
analysis of secondary outcome measures was to evaluate the effect of providing antenatal dietary and lifestyle
advice on cardiometabolic and inflammatory biomarkers.
Methods: We conducted a multicentre trial in which pregnant women who were overweight or obese were
randomised to receive either Lifestyle Advice or Standard Care. We report a range of pre-specified secondary
maternal and newborn cardiometabolic and inflammatory biomarker outcomes. Maternal whole venous blood was
collected at trial entry (mean 14 weeks gestation; non-fasting), at 28 weeks gestation (fasting), and at 36 weeks
gestation (non-fasting). Cord blood was collected after birth and prior to the delivery of the placenta. A range of
cardiometabolic and inflammatory markers were analysed (total cholesterol, triglycerides, non-esterified fatty acids,
high-density lipoprotein cholesterol, insulin, glucose, leptin, adiponectin, C-reactive protein, granulocyte
macrophage-colony stimulating factor, interferon gamma, TNF-α, and interleukins 1β, 2, 4, 5, 6, 8, and 10).
Participants were analysed in the groups to which they were randomised, and were included in the analyses if they
had a measure at any time point.
Results: One or more biological specimens were available from 1951 women (989 Lifestyle Advice and 962
Standard Care), with cord blood from 1174 infants (596 Lifestyle Advice and 578 Standard Care). There were no
statistically significant differences in mean cardiometabolic and inflammatory marker concentrations across
pregnancy and in infant cord blood between treatment groups. Estimated treatment group differences were close
to zero, with 95% confidence intervals spanning a range of differences that were short of clinical relevance. There
was no evidence to suggest that the intervention effect was modified by maternal BMI category.
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Conclusions: Despite our findings, it will be worth considering potential relationships between cardiometabolic
and inflammatory markers and clinical outcomes, including longer-term infant health and adiposity.
Trial Registration: Australian and New Zealand Clinical Trials Registry (ACTRN12607000161426; Date Registered
09/03/2007).
Keywords: Pregnancy, Overweight and obesity, Dietary and lifestyle intervention, Randomised trial, Cardiometabolic
markers, Inflammatory markers
Background
Worldwide, more than 1.46 billion adults [1] are over-
weight or obese. Not only has the prevalence of obesity
increased substantially over the past three decades, there
appears to be no country worldwide in which this trend
has been successfully averted or reversed [2]. Overweight
and obesity are associated with poorer health outcomes
for individuals, including hypertension, cardiovascular
disease and diabetes [3].
Overweight and obesity also represent a significant
health concern for women during pregnancy and child-
birth, with approximately 50% of pregnant women esti-
mated to enter pregnancy with a body mass index (BMI)
above 25 kg/m2 [4–6]. Women who are overweight or
obese during pregnancy are at increased risk of a num-
ber of complications, including gestational diabetes,
hypertension and pre-eclampsia, caesarean birth, and
high infant birth weight [7, 8]. In addition to pregnancy-
specific risks, there is also evidence of a persisting
longer-term health legacy, both for the woman and her
infant. Women who are overweight or obese during
pregnancy are at increased risk of developing diabetes
[9], hypertension and cardiovascular disease in later life
[10, 11]. Maternal obesity also identifies women who are
at increased risk of premature death, largely related to
major cardiovascular events [12]. Furthermore, children
born to women who are overweight or obese have a sig-
nificantly increased risk of both early infant and child
obesity, and its subsequent complications [13–15].
Maternal obesity and gestational diabetes share a similar
metabolic environment, characterised by insulin resist-
ance, hyperglycaemia, hyperlipidaemia and a low-grade
state of chronic inflammation, all of which influence the
availability and transfer of nutrients to the developing
fetus [16]. Importantly, maternal triglyceride concentra-
tions correlate with infant birthweight, independent of
maternal glycaemic status [17], with increased fatty acid
production and placental transfer [16]. Furthermore, a
strong link exists between obesity and altered glucose me-
tabolism, and pro-inflammatory markers such as C-
reactive protein (CRP), interleukin-6 (IL-6) and tumour
necrosis factor alpha (TNF-α) [18–24]. Some of these
molecules antagonise effects of insulin such as leptin or
TNF-α, while others have beneficial effects such as
adiponectin [18–24], with evidence that plasma CRP re-
lates to insulin resistance independent of obesity [24, 25].
Pregnancy is also associated with a transient worsening of
the cardiovascular risk profile including increases in dysli-
pidaemia, insulin resistance, oxidative stress, cytokines
such as IL-6 and TNF-α, and inflammatory markers such
as CRP [26–28]. These elevations in cardiovascular risk
factors during pregnancy are further worsened in clinical
states such as gestational diabetes, pre-eclampsia or obes-
ity, which are associated with a poorer lipid profile, insulin
resistance and elevated high-sensitivity CRP, IL-6 and
TNF-α [29–33]. Overall, however, there is limited research
examining changes in cardiovascular risk factors in these
high risk populations, and the existing literature is gener-
ally confined to small sample sizes, and cross-sectional as-
sessments of women across pregnancy, rather than
longitudinal comparisons.
While features of this metabolic environment have
been described to a limited extent among pregnant
women who are overweight or obese, it is unclear
whether an antenatal dietary and lifestyle intervention
can change or improve the milieu. There is some
evidence that physical activity during pregnancy is asso-
ciated with reduced concentrations of cholesterol, tri-
glycerides [34] and TNF-α [35], while low glycaemic
index and low fat diets during pregnancy have been as-
sociated with alterations in both lipid profiles and CRP
concentrations [36, 37], although such changes have not
been universally reported [38]. Importantly, these studies
have involved relatively lean women. The effect of ante-
natal dietary and lifestyle interventions on cardiometa-
bolic and inflammatory biomarkers in overweight and
obese pregnant women is uncertain, but is of particular
relevance given that this group of women is considered
at high risk of both pregnancy complications, including
pre-eclampsia and gestational diabetes, and the future
development of hypertension, cardiovascular disease and
type-2 diabetes.
The primary findings of the LIMIT randomised trial
evaluating the effect of an antenatal dietary and lifestyle
intervention for overweight or obese pregnant women
have been reported previously. Although there was no
significant difference between groups in relation to the
primary outcome of large-for-gestational-age infants,
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there was a significant 18% relative risk reduction in in-
fant birthweight above 4 kg [39]. Likewise, despite no
difference in gestational weight gain, women who re-
ceived the intervention were successful in improving
their diet and physical activity patterns [40]. The aim of
this pre-specified analysis of secondary outcome mea-
sures was to evaluate the effect of providing antenatal
dietary and lifestyle advice on maternal and infant car-
diometabolic and inflammatory biomarkers.
Methods
Study design
We conducted a multicentre randomised trial in
which women were recruited from the three major
metropolitan maternity hospitals within Adelaide,
South Australia. The methods [41] and primary clin-
ical findings [39, 40, 42] of the LIMIT randomised
trial have been reported in detail previously. The trial
was registered on the Australian and New Zealand
Clinical Trials Registry (ACTRN12607000161426).
Inclusion and exclusion criteria
Women with a BMI ≥ 25 kg/m2 and singleton pregnancy
between 10+0 and 20+0 weeks gestation were eligible for
inclusion. Women with a multiple pregnancy, or who
were diagnosed with type 1 or 2 diabetes prior to preg-
nancy, or who were unable to provide informed consent
were ineligible to participate.
Randomisation, masking and group allocation
The central randomisation service utilised a computer-
generated randomisation schedule, with balanced variable
blocks and stratification for parity (0 versus 1 or more),
BMI at the time of the first antenatal appointment (25–29.9
vs. ≥ 30), and collaborating centre. Women were rando-
mised to either ‘Lifestyle Advice’ or ‘Standard Care’ groups.
Treatment schedules
Lifestyle advice
Women allocated to the Lifestyle Advice group partici-
pated in a comprehensive intervention over pregnancy,
and included combined dietary, physical activity and be-
havioural strategies, delivered by a research dietitian and
trained research assistants [41]. The dietary advice pro-
vided was consistent with current Australian standards
[43]. Physical activity advice encouraged women to in-
crease their walking and incidental activity [44]. The
content of the lifestyle intervention has been described
in detail previously [39, 41, 42].
Standard care
Women allocated to the Standard Care group continued
their pregnancy care according to the guidelines of their
local hospital where they had planned to birth.
Study outcomes
All women presenting for antenatal care had their height
and weight measured, and BMI calculated at the time of
their first antenatal appointment, and again at 36 weeks
gestation. Maternal whole venous blood was collected at
the time of trial entry (mean 14 weeks gestation; non-
fasting), at 28 weeks gestation (fasting), and at 36 weeks
gestation (non-fasting). Cord blood was collected after
birth and prior to the delivery of the placenta. After col-
lection in lithium heparin tubes, each sample was spun
in a refrigerated centrifuge, and aliquots were then
stored frozen at –80 °C until analysis.
Cardiometabolic markers
The following cardiometabolic markers were analysed:
total cholesterol, triglycerides, non-esterified fatty acids
(NEFA), high-density lipoprotein cholesterol (HDL-C), in-
sulin, glucose, leptin, adiponectin and CRP. Very low-
density cholesterol (VLDL-C) was calculated as one-fifth of
the triglycerides. Low-density lipoprotein cholesterol
(LDL-C) was calculated using the Friedewald formula: esti-
mated LDL = [total cholesterol] − [total HDL] − [estimated
VLDL].
Glucose, cholesterol, HDL-C, triglycerides, NEFA and
CRP were measured using commercial kits (Roche Diag-
nostics, Australia or Wako Pure Chemical Industries, Japan
for NEFA) with all assays performed on the automated
Hitachi Auto 912 analyser or Cobas Integra 400 Plus with
appropriate calibrators and quality controls (Roche for
Roche assays; and Wako standard and Sero QC’s for the
NEFA C assay). Insulin concentration was analysed using
highly specific radioimmuno assays (in duplicate, Linco,
Millipore, MA, USA). Plasma leptin (in singulate; HL-81 K;
Millipore, St. Charles, MO, USA) and plasma adiponectin
(in singulate; HADP-61HK; Millipore, St. Charles, MO,
USA) were determined by double antibody radioimmuno-
assay following the methods from the supplier.
Inflammatory markers
The following inflammatory markers were analysed: gran-
ulocyte macrophage-colony stimulating factor (GMCSF),
interferon gamma (IFN-γ), TNF-α, and interleukins (IL)
1β, 2, 4, 5, 6, 8 and 10. Inflammatory marker concentra-
tions were measured in plasma samples using the commer-
cially available Invitrogen Human Ultrasensitive Cytokine
Magnetic 10-Plex Panel (Life Technologies, Carlsbad, CA,
USA). Assays were read using a Luminex 200 Analyser
(Luminex Corporation, Austin, TX, USA) with commer-
cially available calibrators (Life Technologies, Carlsbad,
CA, USA) and an in-house quality control.
Analysis and reporting of results
Analyses were performed on an intention to treat basis, ac-
cording to the treatment group allocated at randomisation
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(Lifestyle Advice or Standard Care). Women were included
in the analysis if they had a specimen available at one or
more time points, and did not withdraw consent to use
their data, or have a miscarriage, or termination of preg-
nancy. Maternal biomarkers (trial entry, 28 weeks, and
36 weeks gestation) were modelled separately to cord
blood measures. Many of the outcomes exhibited highly
skewed distributions, were log transformed prior to ana-
lysis, and are presented as median and interquartile range,
with the estimate of treatment effects back-transformed to
the original scale and reported as ratios of geometric
means (approximately ratios of medians). Outcomes that
were not log transformed are presented as means and
standard deviations, and estimates of treatment effect are
reported as differences in means. Statistical significance
was assessed at the two-sided P < 0.05 level, and no adjust-
ment was made for multiple comparisons. Analyses were
performed using SAS v9.4 (Cary, NC, USA) and Stata v13
(StataCorp, Texas, USA).
Different modelling approaches were taken according
to whether biomarkers were measured at multiple time
points or only at one time, and according to whether
there were any values above or below the assay limits of
detection (tabulation of number of results outside
detection limits for each biomarker can be found in
Additional file 1). For biomarkers measured at only one
time point, linear regression models were used, or Tobit
regression models if there were values outside detection
thresholds. For biomarkers measured at multiple time
points, mixed models (with random effects for participant)
were used to account for correlation due to repeated mea-
sures, and if there were values above or below detection
thresholds, a longitudinal Tobit regression approach was
adopted [45]. A time-by-treatment interaction term was
included in the model to test for differences between
groups in change over time. Separate estimates of treat-
ment effect at each time point were derived, regardless of
the significance of the interaction term.
Both adjusted and unadjusted analyses were performed,
with adjusted analyses including stratification variables
(parity, BMI category, and centre) as well as index of so-
cioeconomic disadvantage (Socio-Economic Indexes for
Areas Index of Relative Socio-Economic Disadvantage
Quintile), maternal smoking status and maternal age at
trial entry, as covariates. These were pre-specified adjust-
ment variables in the main LIMIT analyses, as they were
identified as potential confounders. A range of sensitivity
analyses were performed, including testing the effect of
different modelling assumptions, and testing the effect of
fasting versus non-fasting for maternal glucose, insulin
and triglycerides. Exploratory analyses were also per-
formed to test for modification of the effect of the inter-
vention by maternal BMI category. Estimates of treatment
effect were not substantially different in these analyses.
Sample size
The sample size of 2180 women was pre-determined,
and based on the primary outcome of the trial (large for
gestational age infant) as reported previously [39].
Ethics
Approval was granted by the Women’s and Children’s
Local Health Network Human Research and Ethics
Committee at the Women’s and Children’s Hospital, the
Central Northern Adelaide Health Service Ethics of
Human Research Committee (Lyell McEwin Hospital)
and the Flinders Clinical Research Ethics Committee
(Flinders Medical Centre). All participants provided
written informed consent to participate.
Results
Between June 2008 and December 2011, a total of 2212
women were recruited and randomised to the LIMIT
trial, with 1108 allocated to receive Lifestyle Advice and
1104 to Standard Care (Fig. 1). One or more biological
specimens were available from 1905 women (961 Life-
style Advice and 944 Standard Care), of whom 1224
(64%, 634 Lifestyle Advice and 590 Standard Care) had
measures at all three time points and 1622 (85%, 830
Lifestyle Advice and 792 Standard Care) had at least two
measures. Cord blood was available from 1183 infants
(601 Lifestyle Advice and 582 Standard Care). Detailed
information on number of participants for each outcome
is available in Additional file 1. There were no differ-
ences between the two treatment groups in the baseline
characteristics of participants (Table 1) and women who
provided a biological specimen were similar in their
characteristics to the entire randomised cohort [39]
(data not shown).
Cardiometabolic markers
Mean concentrations of cardiometabolic markers across
pregnancy (Table 2) and in infant cord blood (Table 3)
were similar between the two treatment groups. For
cholesterol, glucose, HDL and LDL (which were not log-
transformed), estimated treatment group differences
were all close to zero at all time points, and 95% confi-
dence intervals (CIs) ranged from a decrease of 0.1 to
0.2 units, to an increase of 0.1 to 0.2 units in the Life-
style Advice group compared to the Standard Care
group; such small differences of this magnitude are not
considered to be clinically meaningful. Similarly, for log-
transformed outcomes (HDL, insulin, adiponectin,
leptin, NEFA and triglycerides), the estimated ratio of
geometric means was very close to 1 in all cases, with
the range of plausible differences indicated by the 95%
CI likewise smaller than would be clinically significant
(less than 10% decrease or increase in the Lifestyle
Advice group compared with the Standard Care group).
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The exception was maternal CRP concentrations,
where statistically significant differences between treat-
ment groups were observed at 28 and 36 weeks, with
the concentrations in the Lifestyle Advice group ap-
proximately 10–15% higher than in the Standard Care
group. However, the CRP concentrations were higher in
the Lifestyle Advice group at baseline, and there was no
evidence that the groups had a different trajectory over
time. Thus, the differences observed at 28 and 36 weeks
are likely due to the differences observed at baseline,
and while likely reflecting a chance effect, they may re-
flect bias introduced by missing data or unmeasured
confounding. In addition, while the difference between
groups was statistically significant, the magnitude of the
difference was small, representing at most an increase of
20%, where concentrations will often vary by 300%.
Results from unadjusted and adjusted analyses were
similar, and there was no evidence to suggest that the
intervention effect was modified by maternal BMI cat-
egory (data not shown).
Inflammatory markers
Mean concentrations in inflammatory markers across
pregnancy and infant cord blood (Table 4) were similar
between the two treatment groups, with no statistically
or clinically significant differences identified. Across all
outcomes at all time points, the estimated geometric
mean ratio between treatment groups was close to 1 (no
difference), with the 95% CIs spanning a range from at
most a 15% decrease in the Lifestyle Advice group rela-
tive to the Standard Care group, to at most a 45% in-
crease in the Lifestyle Advice group relative to the
Standard Care group. Given the degree of variability in
these measures (as can be seen in the interquartile
ranges presented), these differences are not considered
clinically relevant.
Findings of the unadjusted and adjusted analyses were
similar. Again, there was no evidence to suggest that the
intervention effect was modified by maternal BMI cat-
egory (data not shown).
Discussion
Our findings indicate that provision of a dietary and life-
style intervention during pregnancy for women who are
overweight or obese was not associated with clinically
important or statistically significant differences in a
comprehensive and extensive range of maternal and in-
fant cord blood concentrations of cardiometabolic and
inflammatory markers. While mean concentrations of
CRP were significantly higher among women in the
Fig. 1 Flow of participants through the trial
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Lifestyle Advice group at all time points, this is unlikely
to be due to the intervention, and instead is more likely
due to the significant difference at baseline. We also
note that, as is usual for exploratory analyses or analyses
of secondary outcomes, no correction for multiple com-
parisons has been made, and therefore any ‘statistically
significant’ results should be cautiously interpreted in
the context of all reported results.
Our randomised trial is the largest reported to date
evaluating the effects of an antenatal lifestyle interven-
tion for women who are overweight or obese during
pregnancy on maternal or infant cord blood cardiometa-
bolic or inflammatory measures, and utilised robust
methodology, both of which have been limitations in the
research literature to date. The sample size for the trial
was based on the primary outcome, and there has, there-
fore, been no formal calculation of statistical power for
these secondary outcomes. It is therefore possible that
the lack of statistically significant differences is due to
lack of statistical power to detect differences that exist.
However, the sample size of this analysis of secondary
outcomes involves over 1900 women, and almost 1200
infants. We estimate our sample size has power to detect
clinically relevant differences of 0.15 standard deviations
in each maternal, and 0.17 standard deviations in each
infant cord blood, cardiometabolic and inflammatory
marker (80% power; two-sided alpha 0.05), and is larger
than the sample sizes in other reported studies. The lack
of statistically significant findings, and the magnitude of
the estimated effects, suggests that a very large sample
size would be needed to detect differences due to the
intervention, that these effects are likely to be of very
small magnitude, and that the clinical significance of
such small differences is questionable.
The issue of missing data is more complex. It is pos-
sible that women who provided a blood sample, or cord
blood sample (or who provided samples at all time
points) are different to those women who did not, and
that such differences may be responsible for the differ-
ences (or lack thereof ) observed between treatment
groups. While we cannot know for certain whether this
is the case, there are several factors supporting the no-
tion that missing observations are unlikely to be system-
atically different from the observed data. Firstly, the
Table 1 Baseline characteristics of participants contributing one or more biological specimens
Characteristic Lifestyle advice group
n = 992
Standard care group
n = 969
Total
n = 1961
Maternal age (years), mean (SD) 29.3 (5.5) 29.6 (5.6) 29.5 (5.5)
Gestational age at entry (weeks), median (IQR) 14.0 (11.9–16.9) 14.1 (11.9–17.0) 14.1 (11.9–17.0)
Body mass index (kg/m2), median (IQR) 31.2 (28.1–35.9) 31.1 (27.8–35.8) 31.1 (28.0–35.9)
Body mass index category, N (%)
25.0–29.9 409 (41.2) 408 (42.1) 817 (41.7)
30.0–34.9 290 (29.2) 286 (29.5) 576 (29.4)
35.0–39.9 184 (18.5) 159 (16.4) 343 (17.5)
≥40.0 109 (11.0) 116 (12.0) 225 (11.5)
Public patient, N (%) 974 (98.2) 944 (97.4) 1918 (97.8)
Weight (kg), mean (SD) 88.7 (17.3) 88.5 (17.6) 88.6 (17.4)
Height (m), mean (SD) 1.6 (0.1) 1.6 (0.1) 1.6 (0.1)
Race: N (%)
Caucasian 899 (90.6) 885 (91.3) 1784 (91.0)
Asian 21 (2.1) 30 (3.1) 51 (2.6)
Other 72 (7.3) 54 (5.6) 126 (6.4)
Smoker, N (%) 142 (14.3) 116 (12.0) 258 (13.2)
Nulliparous, N (%) 407 (41.0) 389 (40.1) 796 (40.6)
Index of socio-economic disadvantage, N (%)
Unknown 1 (0.1) 1 (0.1) 2 (0.1)
Quintile 1 (Most Disadvantaged) 308 (31.0) 284 (29.3) 592 (30.2)
Quintile 2 242 (24.4) 238 (24.6) 480 (24.5)
Quintile 3 156 (15.7) 149 (15.4) 305 (15.6)
Quintile 4 133 (13.4) 154 (15.9) 287 (14.6)
Quintile 5 (Least Disadvantaged) 152 (15.3) 143 (14.8) 295 (15.0)
Moran et al. BMC Medicine  (2017) 15:32 Page 6 of 12
characteristics of both the women and infants for whom
cardiometabolic and inflammatory measures were avail-
able were similar between treatment groups, and similar
to the full-randomised groups [39]. Similarly, while there
was loss to follow-up for later maternal measures, with
36% of women missing data for at least one time point,
we do not believe that women with incomplete cardio-
metabolic and inflammatory data are systematically dif-
ferent to those with complete data. The reasons for
missing maternal and cord blood data are largely
Table 2 Cardiometabolic markers across pregnancy between randomised treatment groups
Outcome Lifestyle intervention
group
Standard care
group
Estimated effect (95% CI)
(unadjusted)
P value
(unadjusted)
Estimated effect
(95% CI) (adjusted)a
P value
(adjusted)
Cholesterol (mmol/L) 0.856* 0.866*
Baseline 5.48 (1.22) 5.54 (1.22) –0.04 (–0.17, 0.09) 0.521 –0.04 (–0.17, 0.09) 0.512
28 weeks 6.49 (1.47) 6.59 (1.47) –0.07 (–0.20, 0.07) 0.320 –0.06 (–0.19, 0.08) 0.396
36 weeks 6.76 (1.51) 6.83 (1.55) –0.08 (–0.21, 0.06) 0.273 –0.08 (–0.22, 0.06) 0.265
CRPb,c (mg/L) 0.284* 0.338*
Baseline 6.82 (4.04, 11.34) 6.47 (3.36, 11.32) 1.09 (1.01, 1.18) 0.032 1.08 (1.01, 1.17) 0.036
28 weeks 6.40 (3.67, 10.43) 5.92 (3.19, 10.18) 1.12 (1.03, 1.21) 0.006 1.11 (1.03, 1.20) 0.006
36 weeks 5.35 (3.08, 8.85) 4.55 (2.49, 8.18) 1.15 (1.06, 1.25) <0.001 1.14 (1.05, 1.23) 0.001
Glucose (mmol/L) 0.775* 0.690*
Baseline 4.78 (0.94) 4.76 (0.97) 0.01 (–0.10, 0.12) 0.864 0.01 (–0.10, 0.11) 0.910
28 weeks 4.89 (1.32) 4.83 (1.38) 0.06 (–0.05, 0.17) 0.299 0.07 (–0.04, 0.18) 0.227
36 weeks 5.12 (1.19) 5.08 (1.13) 0.04 (–0.08, 0.16) 0.534 0.03 (–0.08, 0.14) 0.622
HDL (mmol/L) 0.634* 0.577*
Baseline 1.43 (0.37) 1.44 (0.36) 0.00 (–0.03, 0.04) 0.976 0.00 (–0.03, 0.04) 0.938
28 weeks 1.49 (0.39) 1.48 (0.40) 0.01 (–0.03, 0.05) 0.589 0.01 (–0.02, 0.05) 0.492
36 weeks 1.37 (0.36) 1.39 (0.39) –0.00 (–0.04, 0.03) 0.807 –0.00 (–0.04, 0.03) 0.860
Insulinb,c (μIU/mL)
28 weeks 18.92 (13.35, 27.16) 18.42 (13.57, 26.07) 1.03 (0.96, 1.10) 0.419 1.02 (0.96, 1.09) 0.471
Adiponectinb (μg/mL) 0.097* 0.117*
Trial entry 8.16 (5.81, 12.15) 8.66 (6.31, 11.96) 0.99 (0.94, 1.04) 0.656 0.99 (0.94, 1.04) 0.650
28 weeks 7.46 (5.07, 10.61) 7.67 (5.60, 10.80) 0.95 (0.89, 1.00) 0.046 0.94 (0.89, 1.00) 0.034
36 weeks 7.83 (5.76, 10.83) 7.98 (5.73, 11.25) 1.00 (0.95, 1.06) 0.989 0.99 (0.94, 1.05) 0.787
Leptinb (ng/mL) 0.257* 0.241*
Trial entry 52.21 (37.76, 69.66) 48.66 (35.12, 68.19) 1.04 (0.99, 1.09) 0.145 1.03 (0.99, 1.08) 0.160
28 weeks 60.87 (43.74, 79.72) 59.41 (43.07, 82.31) 1.00 (0.95, 1.05) 0.933 0.99 (0.94, 1.04) 0.759
36 weeks 54.15 (36.68, 74.20) 54.49 (36.76, 74.39) 1.02 (0.97, 1.08) 0.380 1.02 (0.97, 1.07) 0.538
NEFAb,c (mmol/L)
28 weeks 0.34 (0.21, 0.47) 0.35 (0.23, 0.47) 0.97 (0.90, 1.03) 0.316 0.96 (0.90, 1.03) 0.271
Triglyceridesb (mmol/L)
28 weeks 2.15 (1.73, 2.64) 2.15 (1.69, 2.69) 1.00 (0.96, 1.03) 0.908 1.00 (0.97, 1.04) 0.941
LDL (mmol/L)
28 weeks 4.54 (1.39) 4.65 (1.41) 0.10 (–0.04, 0.24) 0.152 0.09 (–0.05, 0.23) 0.192
aAdjustment for centre, parity, BMI category (stratification variables), Socio-Economic Indexes for Areas Index of Relative Socio-Economic Disadvantage quintile,
smoking status, and maternal age at consent
bOutcomes log transformed for analysis; the descriptives presented for these outcomes are median and interquartile range. Model estimates for these outcomes
have been back-transformed to the original scale, and are therefore ratios of geometric means (approximately ratios of medians) (Intervention/Routine Care)
cOutcomes modelled using Tobit regression due to presence of values below and/or above detectable limits
For outcomes with repeated measures, numbers represent the number of women with a measure at any of the three timepoints (hence included in the model);
for outcomes with only one time point, numbers are the number of women with a measure at that time
All other outcomes, are mean and standard deviation, and model estimates are differences in means
*P values for the time-by-treatment interaction term (i.e. testing whether the effect of treatment differed by time point)
CRP C-reactive protein, HDL high-density lipoprotein cholesterol, NEFA non-esterified fatty acids, LDL low-density lipoprotein cholesterol
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independent of treatment or participant characteristics.
More than 90% of women in the LIMIT study consented
to provide blood and cord blood samples. Missing ma-
ternal blood specimens reflect a range of circumstances,
including inability to attend an appointment, the woman
already having had routine clinical blood samples taken
on the appointment day or, for a small number, assay or
storage freezer malfunction. Missing cord blood samples
largely reflect whether the midwife responsible for con-
ducting the birth was able to obtain sufficient cord blood
over and above that required for clinical purposes.
Additionally, the statistical methodology used for ana-
lyses allows inclusion of participants with incomplete
data, and assumes that data is missing at random (i.e.
that the value of missing observations does not depend
on missingness, conditional on observed data); adjust-
ment for potential confounders increases the likelihood
that this assumption is met.
We have previously reported a significant 18% relative
risk reduction in the incidence of infants with birth
weight above 4.0 [39] and 4.5 kg [42] following improve-
ments in maternal diet (an increased consumption of
fruits and vegetables, and a reduction in the percentage
of dietary energy derived from saturated fats) and phys-
ical activity (equivalent to approximately 20 minutes
brisk walking on most days of the week) [40]. However,
these positive, but relatively modest improvements have
been of insufficient magnitude to measurably alter
cardiometabolic and inflammatory markers across
pregnancy. We postulate that this may, to some ex-
tent, also account for the lack of observed effect on
clinical pregnancy outcomes, including pre-eclampsia
and gestational diabetes [39].
Our findings are in contrast to other smaller studies
reported in the literature involving predominantly lean
pregnant women. Habitual physical activity during early
pregnancy has been associated with a reduction in total
cholesterol and triglycerides [34], while moderate activity
(4 times per week) has been shown to reduce plasma
TNF-α [35]. Consumption of a low glycaemic index diet
[36] and cholesterol lowering diets have [37] both been
associated with alterations in maternal lipid profiles, al-
though these findings are not universal, with others
demonstrating no effect on markers of cardiovascular
disease and glucose homeostasis [38].
Several randomised trials have evaluated the effect of
dietary interventions [38, 46] and metformin [47, 48]
among pregnant women who are obese, and have re-
ported a range of cardiometabolic, and more limited in-
flammatory markers. While the findings of these trials
are largely consistent with those we report, we have in-
cluded a broader range of both cardiometabolic and in-
flammatory markers. Poston et al. [38] demonstrated an
improvement in maternal dietary patterns and a modest
(0.67 kg) difference in gestational weight gain following
provision of antenatal dietary intervention, although this
was not associated with changes in measures of glucose
metabolism, including plasma insulin, or triglycerides
and cholesterol (LDL, HDL, and VLDL) at 28 weeks ges-
tation. In a smaller trial, McCarthy et al. [46] demon-
strated no significant differences in maternal leptin,
adiponectin and CRP measures at 28 weeks gestation
following simple dietary advice. Syngelaki et al. [48] re-
port no difference in fasting glucose concentrations at
28 weeks gestation following use of metformin during
pregnancy, similar to those reported by Chiswick et al.
Table 3 Cord blood cardiometabolic markers between randomised treatment groups
Outcome Lifestyle advice group Standard care group Estimated difference
(95% CI) (unadjusted)
P value
(unadjusted)
Estimated difference
(95% CI) (adjusted)a
P value
(adjusted)
Cholesterol (mmol/L) 1.79 (0.71) 1.80 (0.73) 0.01 (–0.07, 0.09) 0.858 0.01 (–0.07, 0.09) 0.853
CRPb,c mg/L 0.30 (0.30, 0.30) 0.30 (0.27, 0.30) 1.16 (0.74, 1.82) 0.513 1.09 (0.69, 1.72) 0.701
Glucosec (mmol/L) 3.53 (1.38) 3.53 (1.46) 0.00 (–0.16, 0.17) 0.968 –0.00 (–0.16, 0.16) 0.984
HDL (mmol/L) 0.63 (0.25) 0.63 (0.25) –0.01 (–0.03, 0.02) 0.680 –0.01 (–0.04, 0.02) 0.548
Insulinb,c (μIU/mL) 10.04 (6.22, 14.93) 9.41 (5.97, 14.75) 1.06 (0.98, 1.14) 0.142 1.07 (0.99, 1.15) 0.085
NEFAb,c (mmol/L) 0.19 (0.13, 0.27) 0.19 (0.13, 0.28) 0.97 (0.91, 1.04) 0.424 0.96 (0.90, 1.03) 0.276
Triglyceridesb,c (mmol/L) 0.39 (0.27, 0.56) 0.40 (0.26, 0.57) 1.01 (0.94, 1.09) 0.767 0.98 (0.91, 1.05) 0.565
LDL (mmol/L) 1.06 (0.54) 1.07 (0.58) 0.01 (–0.05, 0.08) 0.689 0.02 (–0.05, 0.08) 0.639
Adiponectin (μg/mL) 22.35 (16.93, 28.61) 22.28 (16.77, 28.74) 1.00 (0.95, 1.05) 0.945 1.00 (0.94, 1.05) 0.897
Leptin (ng/mL) 13.06 (7.98, 20.95) 13.13 (7.90, 21.97) 0.98 (0.90, 1.07) 0.607 0.98 (0.90, 1.07) 0.701
aAdjustment for centre, parity, BMI category (stratification variables), Socio-Economic Indexes for Areas Index of Relative Socio-Economic Disadvantage quintile,
smoking status, and maternal age at consent
bOutcomes were log-transformed; descriptives for these outcomes are median and interquartile range, and estimates are ratios of geometric means (approxi-
mately ratios of medians)
All other outcomes are mean and standard deviation, and estimates are differences of means
cOutcomes were modelled using Tobit regression due to presence of values above and/or below detection limits
CRP C-reactive protein, HDL high-density lipoprotein cholesterol, NEFA non-esterified fatty acids, LDL low-density lipoprotein cholesterol
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Table 4 Inflammatory markers across pregnancy and from cord blood between randomised treatment groups
Outcome Lifestyle advice
group
Standard care
group
Unadjusted estimate
(95% CI)
Unadjusted
P value
Adjusted estimate
(95% CI)a
Adjusted
P value
GMCSF (pg/mL) 0.036* 0.016*
Baseline 1.02 (0.36, 4.41) 1.05 (0.36, 4.15) 1.00 (0.84, 1.19) 0.986 1.01 (0.85, 1.20) 0.916
28 weeks 0.99 (0.36, 4.20) 0.92 (0.32, 3.98) 1.06 (0.88, 1.26) 0.545 1.07 (0.90, 1.28) 0.444
36 weeks 0.99 (0.34, 4.06) 0.95 (0.33, 3.79) 1.00 (0.83, 1.19) 0.964 1.01 (0.84, 1.21) 0.913
Cord blood 0.44 (0.23, 0.82) 0.43 (0.24, 0.87) 0.81 (0.66, 0.98) 0.034 0.80 (0.65, 0.97) 0.026
IFN-γ (pg/mL) 0.638* 0.559*
Baseline 0.39 (0.13, 1.28) 0.35 (0.14, 1.24) 1.02 (0.86, 1.21) 0.809 1.02 (0.86, 1.20) 0.834
28 weeks 0.38 (0.12, 1.17) 0.34 (0.13, 1.08) 1.02 (0.86, 1.22) 0.801 1.02 (0.86, 1.21) 0.832
36 weeks 0.35 (0.11, 1.11) 0.30 (0.11, 1.03) 1.09 (0.91, 1.30) 0.333 1.08 (0.90, 1.29) 0.419
Cord blood 0.17 (0.07, 1.43) 0.20 (0.07, 1.29) 0.96 (0.79, 1.17) 0.684 0.93 (0.76, 1.13) 0.476
TNF-α (pg/mL) 0.600* 0.643*
Baseline 0.72 (0.10, 2.69) 0.68 (0.10, 2.53) 1.01 (0.81, 1.25) 0.950 1.00 (0.80, 1.24) 0.967
28 weeks 0.62 (0.10, 2.69) 0.57 (0.10, 2.14) 1.06 (0.85, 1.33) 0.581 1.05 (0.84, 1.32) 0.650
36 weeks 0.60 (0.10, 2.28) 0.47 (0.10, 2.08) 1.16 (0.93, 1.46) 0.195 1.15 (0.91, 1.44) 0.247
Cord blood 0.42 (0.12, 0.87) 0.40 (0.10, 0.82) 1.04 (0.81, 1.32) 0.766 1.04 (0.81, 1.33) 0.770
IL-1β (pg/mL) 0.883* 0.807*
Baseline 0.20 (0.10, 0.59) 0.19 (0.10, 0.53) 1.04 (0.88, 1.23) 0.621 1.04 (0.87, 1.23) 0.687
28 weeks 0.19 (0.10, 0.54) 0.17 (0.10, 0.54) 1.07 (0.90, 1.27) 0.456 1.06 (0.89, 1.26) 0.527
36 weeks 0.18 (0.10, 0.51) 0.14 (0.10, 0.47) 1.11 (0.93, 1.33) 0.234 1.12 (0.93, 1.34) 0.229
Cord blood 1.07 (0.39, 3.04) 0.99 (0.34, 2.76) 1.04 (0.86, 1.24) 0.696 1.02 (0.85, 1.22) 0.855
IL-2 (pg/mL) 0.055* 0.054*
Baseline 0.76 (0.16, 2.76) 0.65 (0.15, 2.61) 0.99 (0.81, 1.21) 0.926 1.00 (0.82, 1.23) 0.969
28 weeks 0.73 (0.12, 2.63) 0.50 (0.12, 2.01) 1.16 (0.94, 1.43) 0.159 1.17 (0.95, 1.45) 0.135
36 weeks 0.66 (0.13, 2.33) 0.45 (0.12, 1.82) 1.16 (0.94, 1.43) 0.179 1.17 (0.94, 1.45) 0.151
Cord blood 0.12 (0.12, 0.31) 0.12 (0.12, 0.30) 0.91 (0.71, 1.16) 0.444 0.91 (0.71, 1.16) 0.458
IL-4 (pg/mL) 0.154* 0.159*
Baseline 1.70 (0.53, 6.14) 1.66 (0.49, 4.89) 1.07 (0.89, 1.27) 0.476 1.06 (0.89, 1.27) 0.530
28 weeks 1.47 (0.47, 5.51) 1.23 (0.38, 4.38) 1.21 (1.01, 1.46) 0.040 1.20 (0.99, 1.44) 0.058
36 weeks 1.37 (0.55, 5.22) 1.26 (0.38, 4.18) 1.15 (0.95, 1.38) 0.152 1.13 (0.93, 1.36) 0.217
Cord blood 1.51 (0.50, 3.53) 1.39 (0.47, 3.70) 0.97 (0.80, 1.19) 0.797 0.96 (0.78, 1.17) 0.665
IL-5 (pg/mL) 0.446* 0.476*
Baseline 0.42 (0.18, 0.98) 0.39 (0.18, 0.96) 1.02 (0.90, 1.17) 0.726 1.05 (0.92, 1.20) 0.500
28 weeks 0.40 (0.18, 0.96) 0.41 (0.18, 0.85) 1.04 (0.91, 1.20) 0.544 1.06 (0.92, 1.22) 0.409
36 weeks 0.39 (0.18, 0.88) 0.31 (0.18, 0.68) 1.13 (0.98, 1.30) 0.088 1.15 (0.99, 1.32) 0.061
Cord blood 0.61 (0.31, 1.15) 0.55 (0.31, 1.03) 1.02 (0.88, 1.18) 0.806 1.03 (0.88, 1.19) 0.736
IL-6 (pg/mL) 0.857* 0.823*
Baseline 1.18 (0.61, 2.18) 1.14 (0.59, 2.07) 1.02 (0.91, 1.13) 0.773 1.02 (0.91, 1.14) 0.738
28 weeks 1.12 (0.63, 2.06) 1.11 (0.63, 2.03) 1.05 (0.94, 1.18) 0.403 1.05 (0.94, 1.18) 0.396
36 weeks 1.33 (0.76, 2.38) 1.26 (0.78, 2.15) 0.99 (0.88, 1.12) 0.911 0.99 (0.88, 1.12) 0.886
Cord blood 4.46 (1.86, 13.86) 4.32 (1.67, 14.10) 1.00 (0.88, 1.14) 0.943 1.00 (0.87, 1.14) 0.956
IL-8 (pg/mL) 0.183* 0.198*
Baseline 7.36 (3.96, 12.06) 7.26 (4.21, 12.22) 0.96 (0.86, 1.08) 0.497 0.96 (0.87, 1.07) 0.482
28 weeks 7.66 (4.42, 13.57) 7.50 (3.76, 12.41) 1.02 (0.91, 1.15) 0.738 1.04 (0.94, 1.16) 0.451
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[47]. While the EMPoWAR trial also demonstrated no
significant differences in maternal cholesterol, HDL,
LDL, triglycerides, leptin or NEFA, women who received
metformin had lower concentrations of CRP and IL-6 at
36 weeks gestation [47]. No statistically significant differ-
ences were identified between the two treatment groups
in cord blood glucose, insulin and CRP [47].
While there is a considerable literature describing as-
sociations between increasing BMI and alterations in the
cardiometabolic and inflammatory profiles [18–25], any
mediating effect of gestational weight gain is less certain.
For example, increasing CRP concentrations have been
reported to be associated with increased gestational
weight gain, although there does not appear to be an
association between weight gain and concentrations of
either TNF-α or IL-6 [49]. Associations between gesta-
tional weight gain and maternal leptin concentrations
also remain unclear, with some authors reporting an as-
sociation with increased weight gain, particularly in the
second trimester of pregnancy [50], while others do not
[51]. Importantly, these relationships may reflect mater-
nal pre-pregnancy BMI, with associations between gesta-
tional weight gain and leptin concentration evident
among normal weight and overweight women, but not
among obese women [52]. We did not control for mater-
nal gestational weight gain when estimating the effect of
the intervention on maternal or infant cardiometabolic
and inflammatory measures, as this was determined after
the time of randomisation. However, we have previously
shown that gestational weight gain was very similar be-
tween women in the lifestyle advice and standard care
groups [39], and we therefore consider it unlikely that
gestational weight gain would have substantially influ-
enced our findings.
The findings of our randomised trial indicate that
provision of an antenatal dietary and lifestyle interven-
tion for women who are overweight or obese was not as-
sociated with any statistically or clinically significant
differences in maternal or infant cord blood cardiometa-
bolic or inflammatory markers. Despite this, it would be
worth considering potential relationships between ma-
ternal and infant cardiometabolic and inflammatory
markers and clinical pregnancy outcomes, in addition to
longer-term infant health and adiposity measures.
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